Quantbot Technologies’s Protagonist Therapeutics PTGX Stock Holding History

Quantbot Technologies’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,303	Closed	-$219K	–	2078
2025 Q3	$219K	Buy	+3,303	New	+$188K	0.01%	1262
2023 Q1	–	Sell	-6,700	Closed	-$73.1K	–	1970
2022 Q4	$73.1K	Buy	6,700 +5,700	+570%	+$48.1K	0.01%	1226
2022 Q3	$8K	Sell	1,000 -8,658	-90%	-$81.9K	﹤0.01%	1449
2022 Q2	$76K	Buy	+9,658	New	+$117K	0.01%	1214
2022 Q1	–	Sell	-13,104	Closed	-$448K	–	1976
2021 Q4	$448K	Buy	+13,104	New	+$414K	0.04%	561
2021 Q2	–	Sell	-954	Closed	-$24K	–	1784
2021 Q1	$24K	Buy	+954	New	+$24.1K	﹤0.01%	1141
2020 Q4	–	Sell	-300	Closed	-$5K	–	1604
2020 Q3	$5K	Buy	+300	New	+$5.63K	﹤0.01%	1190

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Quantbot Technologies's PTGX Position: Q4 2025 in Review

Quantbot Technologies sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 3,303 shares — an estimated $219K sold.

Quantbot Technologies first reported a position in PTGX in Q3 2020 and held it in 7 quarters. The position peaked at $448K in Q4 2021. 313 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

Quantbot Technologies reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
Quantbot Technologies sold 3,303 Protagonist Therapeutics shares in Q4 2025, an estimated $219K.
Quantbot Technologies first reported a position in Protagonist Therapeutics in Q3 2020 and held it in 7 quarters.
Quantbot Technologies's Protagonist Therapeutics position peaked at $448K in Q4 2021.
313 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Quantbot Technologies's 13F filing for Q4 2025, filed 10 Feb 2026.